New Antibiotics for Pneumonia
New Antibiotics for Pneumonia
复制标题
DOI：
10.1016/j.ccm.2018.08.007
复制
发表时间：
2018-12-01
影响因子：
5.7
通讯作者：
Carnelutti, Alessia
中科院分区：
文献类型：
--
作者：
Bassetti, Matteo;Righi, Elda;Carnelutti, Alessia
延迟抗菌药物处方和不适当的治疗可能会导致肺炎的不良预后。在医院感染中，特别是在抗菌药物耐药率高的国家，多重耐药革兰氏阴性菌和革兰氏阳性菌的存在可能会限制充分抗菌治疗的选择。新型抗生素属于已知的抗菌药物类别或具有新颖的作用机制，最近已获得批准或正在开发中。新化合物的优点包括增强的抗耐药细菌活性谱、高肺渗透性、良好的耐受性以及静脉注射至口服序贯治疗的可能性。本文回顾了新批准和研究化合物的特性。
Delayed antimicrobial prescriptions and inappropriate treatment can lead to poor outcomes in pneumonia. In nosocomial infections, especially in countries reporting high rates of antimicrobial resistance, the presence of multidrug-resistant gram negative and gam-positive bacteria can limit options for adequate antimicrobial treatment. New antibiotics, belonging to known classes of antimicrobials or characterized by novel mechanisms of actions, have recently been approved or are under development. Advantages of the new compounds include enhanced spectrum of activity against resistant bacteria, high lung penetration, good tolerability, and possibility for intravenous to oral sequential therapy. This article reviews characteristics of newly approved and investigational compounds.